Search Results - "Laskey, Sarah B."

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure by Ho, Ya-Chi, Shan, Liang, Hosmane, Nina N., Wang, Jeffrey, Laskey, Sarah B., Rosenbloom, Daniel I.S., Lai, Jun, Blankson, Joel N., Siliciano, Janet D., Siliciano, Robert F.

    Published in Cell (24-10-2013)
    “…Antiretroviral therapy fails to cure HIV-1 infection because latent proviruses persist in resting CD4+ T cells. T cell activation reverses latency, but <1% of…”
    Get full text
    Journal Article
  2. 2

    A mechanistic theory to explain the efficacy of antiretroviral therapy by Laskey, Sarah B., Siliciano, Robert F.

    Published in Nature reviews. Microbiology (01-11-2014)
    “…Combination antiretroviral therapy (cART) has revolutionized the treatment of HIV-1 infection, but the mechanistic basis of successful treatment is poorly…”
    Get full text
    Journal Article
  3. 3

    Evaluating Clonal Expansion of HIV-Infected Cells: Optimization of PCR Strategies to Predict Clonality by Laskey, Sarah B, Pohlmeyer, Christopher W, Bruner, Katherine M, Siliciano, Robert F

    Published in PLoS pathogens (01-08-2016)
    “…In HIV-infected individuals receiving suppressive antiretroviral therapy, the virus persists indefinitely in a reservoir of latently infected cells. The…”
    Get full text
    Journal Article
  4. 4

    Cross-reactive microbial peptides can modulate HIV-specific CD8+ T cell responses by Pohlmeyer, Christopher W, Laskey, Sarah B, Beck, Sarah E, Xu, Daniel C, Capoferri, Adam A, Garliss, Caroline C, May, Megan E, Livingston, Alison, Lichmira, Walt, Moore, Richard D, Leffell, M Sue, Butler, Nicholas J, Thorne, Jennifer E, Flynn, John A, Siliciano, Robert F, Blankson, Joel N

    Published in PloS one (21-02-2018)
    “…Heterologous immunity is an important aspect of the adaptive immune response. We hypothesized that this process could modulate the HIV-1-specific CD8+ T cell…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry by Tennen, Ruth I., Laskey, Sarah B., Koelsch, Bertram L., McIntyre, Matthew H., Tung, Joyce Y.

    Published in Scientific reports (06-05-2020)
    “…Current guidelines recommend BRCA1 and BRCA2 genetic testing for individuals with a personal or family history of certain cancers. Three BRCA1/2 founder…”
    Get full text
    Journal Article
  7. 7

    Defective proviruses rapidly accumulate during acute HIV-1 infection by Bruner, Katherine M, Murray, Alexandra J, Pollack, Ross A, Soliman, Mary G, Laskey, Sarah B, Capoferri, Adam A, Lai, Jun, Strain, Matthew C, Lada, Steven M, Hoh, Rebecca, Ho, Ya-Chi, Richman, Douglas D, Deeks, Steven G, Siliciano, Janet D, Siliciano, Robert F

    Published in Nature medicine (01-09-2016)
    “…Bruner et al . report that defective HIV-1 proviruses predominate in early infection, even when antiretroviral therapy is initiated in the first months after…”
    Get full text
    Journal Article
  8. 8

    Quantitative evaluation of the antiretroviral efficacy of dolutegravir by Laskey, Sarah B, Siliciano, Robert F

    Published in JCI insight (17-11-2016)
    “…The second-generation HIV-1 integrase strand transfer inhibitor (InSTI) dolutegravir (DTG) has had a major impact on the treatment of HIV-1 infection. Here we…”
    Get full text
    Journal Article
  9. 9

    Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance by Gray, William T, Frey, Kathleen M, Laskey, Sarah B, Mislak, Andrea C, Spasov, Krasimir A, Lee, Won-Gil, Bollini, Mariela, Siliciano, Robert F, Jorgensen, William L, Anderson, Karen S

    Published in ACS medicinal chemistry letters (08-10-2015)
    “…Catechol diether compounds have nanomolar antiviral and enzymatic activity against HIV with reverse transcriptase (RT) variants containing K101P, a mutation…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12